FDA Lifts Clinical Hold on Aardvark’s ARD-101 for Prader-Willi Syndrome

The FDA lifted the clinical hold on ARD-101, allowing Aardvark Therapeutics to resume development for Prader-Willi Syndrome after cardiac safety studies.